U.S. Trade Representative Katherine Tai took to the Financial Times this week to re-state her position, and President Biden’s, that from now on, global trade has to benefit the common good.
When drugs are pulled from pharmacy shelves, it’s somewhat of a well-kept secret that it is the pharmaceutical company that voluntarily warns buyers of the potential harm from the defect.
The U.S. Senate Finance Subcommittee for International Trade, Customs, and Global Competitiveness took a one-sided view on the de minimis exemption in a hearing on Tuesday, rejecting anything but technocratic changes to the global duty-free rule for small packages priced under $800.
Treasury Secretary Janet Yellen was in Europe this week on a charm offensive from Washington, trying to convince leaders there to join forces in going after China on trade.
A new trade policy isn’t just emerging; it’s emerged. Six years after former President Donald Trump and his chief trade diplomat Robert Lighthizer imposed tariffs on nearly $400 billion worth of imported goods from China, President Biden has done the same.
In six short years, there is now a strong, bipartisan consensus that trade with China is a serious issue that is harming our nation, workers, and producers.
Generic drug exporter Zydus Lifesciences received poor marks again in April following a Food and Drug Administration inspection of its lab in Vadodara, a city in Gujarat state on India’s western coast.
The Veterans Health Administration (VHA) banned the use of plastic syringes made in China on April 23 due to safety concerns, ahead of a warning letter dated April 24 to Ohio-based importer Cardinal Health by the Food and Drug Administration.
Treasury Secretary Janet Yellen faced a round of questioning that saw the Democrats applaud her, and the Republicans admonish her for a little over two hours during Tuesday’s House Ways & Means Committee hearing.